AKT1 and neoplasm: For colorectal cancer, everolimus inhibits the PI3K/AKT/mTOR axis to disrupt cellular transformation and tumor progression while reducing drug resistance, highlighting its therapeutic potential in this malignancy (Bahrami et al., 2018).